Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249–59. https://doi.org/10.1016/s0014-2999(97)01108-4.

Article  CAS  PubMed  Google Scholar 

Pataricza J, Hõhn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52:213–7. https://doi.org/10.1211/0022357001773715.

Article  CAS  PubMed  Google Scholar 

Chan CC, Lee KT, Ho WJ, Chan YH, Chu PH. Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study. Ann Intensive Care. 2021;11:27. https://doi.org/10.1186/s13613-021-00810-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bouchez S, Fedele F, Giannakoulas G, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018;32:617–24. https://doi.org/10.1007/s10557-018-6838-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455–69. https://doi.org/10.1093/eurheartj/eht386.

Article  PubMed  Google Scholar 

Cholley B, Bojan M, Guillon B, et al. Overview of the current use of levosimendan in France: a prospective observational cohort study. Ann Intensive Care. 2023;13:69. https://doi.org/10.1186/s13613-023-01164-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Honore PM, Redant S, Moorthamers S, et al. What should clinicians know about the renal effect and the mechanism of action of levosimendan? Expert Opin Drug Saf. 2021;20:1459–61. https://doi.org/10.1080/14740338.2021.1986483.

Article  PubMed  Google Scholar 

Puttonen J, Laine T, Ramela M, et al. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. Eur J Pharm Sci : Off J Eur Fed Pharma Sci. 2007;32:271–7. https://doi.org/10.1016/j.ejps.2007.08.003.

Article  CAS  Google Scholar 

Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46:235–46. https://doi.org/10.2165/00003088-200746030-00004.

Article  CAS  PubMed  Google Scholar 

Damman K, Voors AA. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to “Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al.” Cardiovasc Drugs Ther. 2007;21:403–4. https://doi.org/10.1007/s10557-007-6070-y.

Article  CAS  PubMed  Google Scholar 

Honore PM, Gutierrez LB, Redant S, Kaefer K, Gallerani A, De Bels D. How levosimendan can improve renal function? Crit Care. 2019;23:331. https://doi.org/10.1186/s13054-019-2642-z.

Article  PubMed  PubMed Central  Google Scholar 

Gamilla-Crudo AK, Kadambi PV, Prough DS. Test driving levosimendan as the new “kidney protector”: first impressions. Crit Care Med. 2013;41:2445–6. https://doi.org/10.1097/CCM.0b013e3182963fdc.

Article  PubMed  Google Scholar 

Masarone D, Kittleson M, Pollesello P, Tedford RJ, Pacileo G. Use of levosimendan in patients with pulmonary hypertension: what is the current evidence? Drugs. 2023;83:195–201. https://doi.org/10.1007/s40265-022-01833-w.

Article  CAS  PubMed  Google Scholar 

Burkhoff D, Rich S, Pollesello P, Papp Z. Levosimendan-induced venodilation is mediated by opening of potassium channels. ESC heart failure. 2021;8:4454–64. https://doi.org/10.1002/ehf2.13669.

Article  PubMed  PubMed Central  Google Scholar 

Grossini E, Molinari C, Pollesello P, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342:376–88. https://doi.org/10.1124/jpet.112.193961.

Article  CAS  PubMed  Google Scholar 

Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290:F1453–62. https://doi.org/10.1152/ajprenal.00485.2005.

Article  CAS  PubMed  Google Scholar 

Tawfik MK, Makary S, Keshawy MM. Upregulation of antioxidant nuclear factor erythroid 2-related factor 2 and its dependent genes associated with enhancing renal ischemic preconditioning renoprotection using levosimendan and cilostazol in an ischemia/reperfusion rat model. Arch Med Sci : AMS. 2021;17:1783–96. https://doi.org/10.5114/aoms/111373.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yakut N, Yasa H, Bahriye Lafci B, et al. The influence of levosimendan and iloprost on renal ischemia-reperfusion: an experimental study. Interact Cardiovasc Thorac Surg. 2008;7:235–9. https://doi.org/10.1510/icvts.2007.161356.

Article  PubMed  Google Scholar 

Gecit I, Kavak S, Yüksel MB, et al. Effect of short-term treatment with levosimendan on oxidative stress in renal tissues of rats. Toxicol Ind Health. 2014;30:47–51. https://doi.org/10.1177/0748233712451773.

Article  CAS  PubMed  Google Scholar 

Onody P, Aranyi P, Turoczi Z, et al. Levosimendan administration in limb ischemia: multicomponent signaling serving kidney protection. PLoS ONE. 2016;11:e0163675. https://doi.org/10.1371/journal.pone.0163675.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian L, Wang S, Zhao L, et al. Renoprotective effects of levosimendan on acute kidney injury following cardiac arrest via anti-inflammation, anti-apoptosis, and ERK activation. FEBS Open Bio. 2021;11:2236–44. https://doi.org/10.1002/2211-5463.13227.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Tian L, Wang S, Yang W, Lu X, Zhu C. Levosimendan in rats decreases acute kidney injury after cardiopulmonary resuscitation by improving mitochondrial dysfunction. Transl Androl Urol. 2021;10:3010–20. https://doi.org/10.21037/tau-21-443.

Article  PubMed  PubMed Central  Google Scholar 

Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431–5. https://doi.org/10.1007/s10557-007-6066-7.

Article  CAS  PubMed  Google Scholar 

Hou ZQ, Sun ZX, Su CY, et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther. 2013;31:108–14. https://doi.org/10.1111/1755-5922.12001.

Article  CAS  PubMed  Google Scholar 

Fedele F, Bruno N, Brasolin B, Caira C, D’Ambrosi A, Mancone M. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16:281–8. https://doi.org/10.1002/ejhf.9.

Article  CAS  PubMed  Google Scholar 

Zangrillo A, Alvaro G, Belletti A, et al. Effect of levosimendan on renal outcome in cardiac surgery patients with chronic kidney disease and perioperative cardiovascular dysfunction: a substudy of a multicenter randomized trial. J Cardiothorac Vasc Anesth. 2018;32:2152–9. https://doi.org/10.1053/j.jvca.2018.02.039.

Article  CAS  PubMed  Google Scholar 

Zhang H, Jiang L, Fu R, et al. Impact of levosimendan on efficacy and renal function in acute heart failure according to renal function: a perspective, multi-center, real-world registry. Front Cardiovasc Med. 2022;9:986039. https://doi.org/10.3389/fcvm.2022.986039.